Please login to the form below

Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos JAK contender scores in RA trial

The first JAK inhibitor on the market is Pfizer’s Xeljanz (tofacitinib) and already earns in excess of $1bn a year in RA revenues.

Latest news

New data keeps AbbVie’s star pipeline therapies on track

follow-up to its marketed JAK inhibitor Xeljanz (tofacitinib). ... And for good measure Pfizer is developing a topical formulation of Xeljanz for atopic dermatitis, an approach also taken by Torii Pharma with its phase II candidate JTE-052.
BMS psoriasis drug hits the mark in phase II

Pfizer’s Xeljanz (tofacitinib) has been approved for psoriatic arthritis but was turned down by the FDA for psoriasis in 2015.
Gilead, Galapagos JAK inhibitor clears phase II test

related. First-to-market JAK inhibitor Xeljanz (tofacitinib) from Pfizer has already achieved $1bn-plus sales in RA, and with Olumiant somewhat hamstring by the safety issue on its label analysts
Pfizer CEO reckons rebates will disappear, and that’s a positive

Pfizer’s chief executive Ian Read (pictured below) has said that he expects drug price rebates will eventually disappear in the US, and that could give drugs like arthritis drug Xeljanz ... formulary is offering a large rebate – something that Read
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar

Will Pfizer spark price war with its Herceptin biosimilar?

More from news
Approximately 20 fully matching, plus 45 partially matching documents found.

Latest Intelligence

Pharma deals during September 2013

antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Brand leaders in RA will lose market share, predict rheumatologists

JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. ... The EMA’ s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Senior Account Manager – Healthcare Advertising: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Sudler London - Senior Medical Writer: Competitive

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Healthcare PR Senior Account Manager: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Medical Writers Required - Hertfordshire: Competitive

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Associate Scientific Director: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Graduate Scientific Editor: DOE

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Healthcare PR Director: £100, 000 – £120, 000 benefits

Systematic Review Lead- London: Negotiable

Senior Writer, Healthcare Advertising, London: Excellent package

Account Director, Healthcare Advertising Agency: Salary TBC

Account Manager: Negotiable

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Medical Writer, MedComms Agency: Salary TBC

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....